Amgen Inc (AMGN) 161.78 $AMGN Midday Glance: Bi
Post# of 64068
Posted On: 03/16/2015 1:31:01 PM
Amgen Inc (AMGN) 161.78 $AMGN
Midday Glance: Biotechnology companies
AP - 11 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)
Cramer: 'Remarkable' Data from Regeneron, Amgen; Sees Edward Lifesciences Going Higher
at The Street - 2 hrs 26 mins ago
TheStreet's Jim Cramer analyzes Regeneron and Amgen's promising cholesterol drugs, to Mobileye's secondary offering and Oppenheimer's downgrade of Garmin.
GRMN: 48.30 (+0.30), EW: 147.63 (+12.28), AMGN: 161.78 (+7.52), MBLY: 42.09 (+0.46), REGN: 446.44 (+17.06)
Early Glance: Biotechnology companies
AP - 2 hrs 56 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 419.99 (+6.64), BBC: 33.77 (+0.32), BIB: 166.75 (+5.88), XBI: 230.59 (+2.16), AMGN: 161.78 (+7.52)
Regeneron's alirocumab shows durable effect in lowering "bad" cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT
AMGN: 161.78 (+7.52), SNY: 48.70 (+1.63), REGN: 446.44 (+17.06)
1 Expensive Biotech Stock Worth Buying
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 15, 10:01AM CDT
Source: Ligand Pharmaceuticals Why buy something that's expensive? There are multiple answers to this question, of course. I'd contend that the best response of all is that it makes sense to buy an expensive item if its value is likely to...
AMGN: 161.78 (+7.52), LGND: 75.17 (+0.18), GSK: 46.91 (+0.54)
Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha(TM) (evolocumab) In The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha(TM) (evolocumab), a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. These data were presented today at a Late-Breaking Clinical Trial session at the American College of Cardiology's 64th Annual Scientific Session (ACC.15) and published in the New England Journal of Medicine. A two-year analysis of Repatha safety and tolerability data from the longest proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor trial to date (OSLER-1) was also presented.
AMGN: 161.78 (+7.52)
Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 419.99 (+6.64), ESRX: 83.50 (+2.13), GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), ABBV: 58.93 (+0.93), CELG: 120.02 (+2.29)
Japanese study shows Amgen's evolocumab lowers bad cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Sat Mar 14, 8:17PM CDT
AMGN: 161.78 (+7.52)
New Detailed Data From Phase 3 Study Show Amgen's Repatha(TM) (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol
PR Newswire - Sat Mar 14, 11:30AM CDT
Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha(TM) (evolocumab), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and high cholesterol. Data from the study showed subcutaneous Repatha 140 mg every two weeks or 420 mg monthly, compared to placebo, in combination with different daily doses of atorvastatin, reduced low-density lipoprotein cholesterol (LDL-C) by 67 to 76 percent from baseline at week 12 and at the mean of weeks 10 and 12. The data were presented at the American College of Cardiology's 64th Annual Scientific Session (ACC.15).
AMGN: 161.78 (+7.52)
3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 419.99 (+6.64), BBC: 33.77 (+0.32), BIB: 166.75 (+5.88), XBI: 230.59 (+2.16), IBB: 351.70 (+6.37), AMGN: 161.78 (+7.52)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 255.72 (+0.74), CLDX: 30.35 (+0.61), EPZM: 22.42 (-0.60), STML: 16.23 (+0.22), JNJ: 100.53 (+1.32), ABBV: 58.93 (+0.93), INFI: 16.05 (+0.59), PTLA: 41.44 (+0.74), INCY: 90.04 (+0.73), PFE: 34.45 (+0.45), IMGN: 7.66 (-0.19), AMGN: 161.78 (+7.52), LLY: 71.13 (+1.24), BMY: 67.86 (+0.99), GSK: 46.91 (+0.54), SGEN: 38.93 (+0.62), GILD: 100.94 (+1.33), KITE: 63.24 (+0.15), MRK: 57.05 (+0.85), TEVA: 60.60 (+0.60), CELGZ: 3.02 (-0.03), KPTI: 30.65 (+2.57), NVS: 97.93 (+0.89)
Amgen Has Been Flat For The Past 4 Months
Abba's Aces - at Seeking Alpha - Fri Mar 13, 8:39AM CDT
AMGN: 161.78 (+7.52)
Patient enrollment complete in trial expansion phase of Cytokinetics' heart drug
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:19AM CDT
CYTK: 7.73 (-0.25), AMGN: 161.78 (+7.52)
Final Glance: Biotechnology companies
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)
Akebia Completes Enrolment in Phase II Renal Anemia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 3:45PM CDT
Akebia Therapeutics (AKBA) completed enrolment in the third and final cohort of a phase II study on AKB-6548, being evaluated for treating patients with anemia related to chronic kidney disease undergoing dialysis.
LCI: 64.94 (-0.09), AMGN: 161.78 (+7.52), AKBA: 12.86 (-0.38), AMAG: 54.52 (-0.48)
Midday Glance: Biotechnology companies
AP - 11 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)
Cramer: 'Remarkable' Data from Regeneron, Amgen; Sees Edward Lifesciences Going Higher
at The Street - 2 hrs 26 mins ago
TheStreet's Jim Cramer analyzes Regeneron and Amgen's promising cholesterol drugs, to Mobileye's secondary offering and Oppenheimer's downgrade of Garmin.
GRMN: 48.30 (+0.30), EW: 147.63 (+12.28), AMGN: 161.78 (+7.52), MBLY: 42.09 (+0.46), REGN: 446.44 (+17.06)
Early Glance: Biotechnology companies
AP - 2 hrs 56 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 419.99 (+6.64), BBC: 33.77 (+0.32), BIB: 166.75 (+5.88), XBI: 230.59 (+2.16), AMGN: 161.78 (+7.52)
Regeneron's alirocumab shows durable effect in lowering "bad" cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT
AMGN: 161.78 (+7.52), SNY: 48.70 (+1.63), REGN: 446.44 (+17.06)
1 Expensive Biotech Stock Worth Buying
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 15, 10:01AM CDT
Source: Ligand Pharmaceuticals Why buy something that's expensive? There are multiple answers to this question, of course. I'd contend that the best response of all is that it makes sense to buy an expensive item if its value is likely to...
AMGN: 161.78 (+7.52), LGND: 75.17 (+0.18), GSK: 46.91 (+0.54)
Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha(TM) (evolocumab) In The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha(TM) (evolocumab), a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. These data were presented today at a Late-Breaking Clinical Trial session at the American College of Cardiology's 64th Annual Scientific Session (ACC.15) and published in the New England Journal of Medicine. A two-year analysis of Repatha safety and tolerability data from the longest proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor trial to date (OSLER-1) was also presented.
AMGN: 161.78 (+7.52)
Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 419.99 (+6.64), ESRX: 83.50 (+2.13), GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), ABBV: 58.93 (+0.93), CELG: 120.02 (+2.29)
Japanese study shows Amgen's evolocumab lowers bad cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Sat Mar 14, 8:17PM CDT
AMGN: 161.78 (+7.52)
New Detailed Data From Phase 3 Study Show Amgen's Repatha(TM) (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol
PR Newswire - Sat Mar 14, 11:30AM CDT
Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha(TM) (evolocumab), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and high cholesterol. Data from the study showed subcutaneous Repatha 140 mg every two weeks or 420 mg monthly, compared to placebo, in combination with different daily doses of atorvastatin, reduced low-density lipoprotein cholesterol (LDL-C) by 67 to 76 percent from baseline at week 12 and at the mean of weeks 10 and 12. The data were presented at the American College of Cardiology's 64th Annual Scientific Session (ACC.15).
AMGN: 161.78 (+7.52)
3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 419.99 (+6.64), BBC: 33.77 (+0.32), BIB: 166.75 (+5.88), XBI: 230.59 (+2.16), IBB: 351.70 (+6.37), AMGN: 161.78 (+7.52)
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 255.72 (+0.74), CLDX: 30.35 (+0.61), EPZM: 22.42 (-0.60), STML: 16.23 (+0.22), JNJ: 100.53 (+1.32), ABBV: 58.93 (+0.93), INFI: 16.05 (+0.59), PTLA: 41.44 (+0.74), INCY: 90.04 (+0.73), PFE: 34.45 (+0.45), IMGN: 7.66 (-0.19), AMGN: 161.78 (+7.52), LLY: 71.13 (+1.24), BMY: 67.86 (+0.99), GSK: 46.91 (+0.54), SGEN: 38.93 (+0.62), GILD: 100.94 (+1.33), KITE: 63.24 (+0.15), MRK: 57.05 (+0.85), TEVA: 60.60 (+0.60), CELGZ: 3.02 (-0.03), KPTI: 30.65 (+2.57), NVS: 97.93 (+0.89)
Amgen Has Been Flat For The Past 4 Months
Abba's Aces - at Seeking Alpha - Fri Mar 13, 8:39AM CDT
AMGN: 161.78 (+7.52)
Patient enrollment complete in trial expansion phase of Cytokinetics' heart drug
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:19AM CDT
CYTK: 7.73 (-0.25), AMGN: 161.78 (+7.52)
Final Glance: Biotechnology companies
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)
Akebia Completes Enrolment in Phase II Renal Anemia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 3:45PM CDT
Akebia Therapeutics (AKBA) completed enrolment in the third and final cohort of a phase II study on AKB-6548, being evaluated for treating patients with anemia related to chronic kidney disease undergoing dialysis.
LCI: 64.94 (-0.09), AMGN: 161.78 (+7.52), AKBA: 12.86 (-0.38), AMAG: 54.52 (-0.48)
(0)
(0)